Rating Change
Canaccord Genuity reiterated its Buy rating on 10x Genomics, Inc. (NASDAQ:TXG) on August 10, 2026.
Canaccord Genuity reiterated its Buy rating on 10x Genomics, Inc. (NASDAQ:TXG) on August 10, 2026.

At publication ·
10x Genomics, Inc. (NASDAQ:TXG) · reiterate
At a glance
Canaccord Genuity reiterated its Buy rating on 10x Genomics, Inc. (NASDAQ:TXG) on August 10, 2026.
10x Genomics, Inc. operates in the Healthcare sector. The stock currently trades at $56.35 with a market capitalization of $2.0B.
Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for 10x Genomics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 3 Buy, 7 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 10, 2026 | Canaccord Genuity | Buy | N/A |
| Aug 07, 2026 | Citigroup | Neutral | N/A |
| Aug 07, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Jul 17, 2026 | Leerink Partners | Market Perform | N/A |
| Jul 14, 2026 | Canaccord Genuity | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View TXG Stock Page
A rating of Buy from Canaccord Genuity reflects the analyst's outlook on 10x Genomics, Inc. (NASDAQ:TXG). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TXG forecast page.
Current market data
NASDAQ · TXG
$66.38
Down: -$0.91 · -1.35%
Live quote updated
Keep reading